NCT04932863View on ClinicalTrials.gov

BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment

CompletedOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

March 15, 2022

Study Completion Date

March 15, 2023

Conditions
NeoplasmsCancer, Treatment-Related
Interventions
BIOLOGICAL

BNT162b2 mRNA Covid-19 Vaccine

Two injections, 21 days apart, of the BNT162b2 vaccine 30 μg per dose in the deltoid muscle.

Trial Locations (1)

16128

E.O. Ospedali Galliera, Genova

All Listed Sponsors
collaborator

Universita degli Studi di Genova

OTHER

lead

Ente Ospedaliero Ospedali Galliera

OTHER

NCT04932863 - BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment | Biotech Hunter | Biotech Hunter